Michael Ackermann is Director at Tarsus Pharmaceuticals, Inc. (TARS). They have made 6 open-market trades across 1 company since 2021, most recently 2022-06-15.
CIK 0001791249
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.4M since 2022, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | BUY | 2022-05-05 | 2022-05-09 | $13.50 | $1.4M | +14.1% | +24.9% | +50.2% |
| TARS | SELL | 2021-12-01 | 2021-12-03 | $24.48 | $253K | +6.1% | -2.2% | -23.4% |
| TARS | SELL | 2021-11-01 | 2021-11-03 | $27.79 | $300K | -10.0% | -13.0% | -27.3% |
| TARS | SELL | 2021-10-12 | 2021-10-14 | $26.35 | $267K | +1.9% | -10.2% | -22.7% |
| TARS | SELL · 10b5-1 | 2021-10-08 | 2021-10-12 | $25.03 | $5K | +0.4% | +0.5% | -18.9% |
| TARS | SELL | 2021-09-01 | 2021-09-03 | $25.24 | $294K | -16.1% | -20.2% | -3.5% |
| TARS | SELL · 10b5-1 | 2021-08-11 | 2021-08-12 | $25.15 | $16K | -8.6% | -7.6% | +7.4% |
| TARS | SELL | 2021-08-06 | 2021-08-10 | $25.00 | $96K | -2.8% | -6.5% | +13.8% |
| TARS | SELL · 10b5-1 | 2021-08-05 | 2021-08-06 | $25.00 | $32K | +1.1% | +2.6% | +10.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.